Ciprofloxacin was subjected to a multilaboratory study designed to determine its in vitro susceptibility criteria for Neisseria gonorrhoeae and its quality control parameters for both agar dilution and disk diffusion susceptibility testing for this species. All clinical isolates were susceptible, i.e., MICs were s0. Ciprofloxacin has been demonstrated to be effective in the treatment of gonococcal infections, including those caused by penicillinase-producing Neisseria gonorrhoeae (2, 7, 11, 12) . The Centers for Disease Control has listed ciprofloxacin among the alternative drugs for therapy of gonorrhea (3).
Ciprofloxacin has been demonstrated to be effective in the treatment of gonococcal infections, including those caused by penicillinase-producing Neisseria gonorrhoeae (2, 7, 11, 12) . The Centers for Disease Control has listed ciprofloxacin among the alternative drugs for therapy of gonorrhea (3) .
The interpretive criteria and quality control parameters for ciprofloxacin susceptibility testing in vitro are well established for nonfastidious rapidly growing aerobic and facultatively anaerobic bacteria (9, 10) . Such criteria and parameters are not yet established for N. gonorrhoeae. The purposes of the present study were (i) to develop interpretive criteria for ciprofloxacin susceptibility testing of N. gonorrhoeae by agar dilution and disk diffusion methods and (ii) to develop quality control parameters for both methods by multilaboratory testing in accordance with the recommendations of the National Committee for Clinical Laboratory Standards (NCCLS) (8) .
MATERIALS AND METHODS
Ciprofloxacin was provided as a standardized powder by Miles, Inc., West Haven, Conn. Susceptibility testing was performed in accordance with the methods recommended by the NCCLS for agar dilution and disk diffusion testing of N. gonorrhoeae (9, 10 5 tests with the GC agar lot common to all facilities. Thus, each laboratory generated 150 zone diameter measurements with 5-,ug ciprofloxacin disks using its unique lot of GC agar and 15 measurements with the common lot of GC agar.
RESULTS
The ciprofloxacin MICs for the 102 clinical N. gonorrhoeae isolates were all s0.06 ,ug/ml (susceptible). Penicillinase production appeared to have no effect on ciprofloxacin MICs, since median and modal ciprofloxacin MICs were 0.008 ,ug/ml for both penicillinase-producing and penicillinase-negative, penicillin-susceptible N. gonorrhoeae strains. Penicillinase-negative, penicillin-resistant strains, however, were somewhat less susceptible to ciprofloxacin; the ciprofloxacin modal and median MICs for that group were both 0.015 ,ug/ml. All isolates for which ciprofloxacin MICs were 0.06 ,ug/ml were penicillinase-negative, penicillin-resistant strains. For the 22 isolates with in vitro-selected resistance, ciprofloxacin MICs ranged from 0.125 to .2.0 ,ug/ml. All 102 susceptible clinical isolates had zone diameters of inhibition around the 5-,ug ciprofloxacin disks of .36 mm; by contrast, all 22 laboratory-induced resistant strains had zone diameters of c35 mm (Fig. 1) .
The results of replicate ciprofloxacin agar dilution testing of the two quality control organisms are summarized in Table 1 . The ciprofloxacin MICs generated for N. gonorrhoeae ATCC 49226 ranged from .0.0005 to 0.008 p,g/ml, a 5-dilution range. On the other hand, the ciprofloxacin MICs for S. aureus ATCC 29213 ranged from 0.12 to 0.5 ,ug/ml, a 3-dilution range that includes concentrations that are likely to be tested in most laboratories.
The data from replicate ciprofloxacin disk diffusion susceptibility testing with two quality control strains are summarized in Table 2 (2, 11, 12) . In these studies, the N. gonorrhoeae isolates were all inhibited by s0.03 p.g of ciprofloxacin per ml in vitro. Strains that are more resistant to ciprofloxacin have been described recently (5, 6) , but the clinical efficacy of ciprofloxacin in treating infections due to such strains is not yet known. Because ciprofloxacin-resistant clinical isolates were not available, ciprofloxacin resistance was induced in vitro, and resistant strains were then tested by both disk diffusion and agar dilution methods. Agar dilution data are included in Fig. 1 aureus ATCC 29213, however, yielded ciprofloxacin MICs of 0.12 to 0.5 ,ug/ml. This 3-dilution range is well within the range of routine susceptibility testing of this drug, and therefore, testing with this organism is recommended for quality control purposes. This is the same range that is currently recommended by the NCCLS for control of dilution tests using Mueller-Hinton broth (10). With 5-,ug ciprofloxacin disks, the mean zone diameter of inhibition was 53.0 mm when N. gonorrhoeae ATCC 49226 was repeatedly tested in five laboratories. The standard deviation for all laboratories was 2.31 mm. By the method of Gavan et al. (4) , the calculated acceptable range for this strain is 48 to 58 mm. With this as a proposed acceptable quality control range, 99% of the test results in this study would be considered acceptable. The mean zone diameter (standard deviation) for S. aureus ATCC 25923 was 24.0 (1.07) mm. By the same calculation procedure, the proposed acceptable quality control range for this strain is 22 to 26 mm. With this range, 98% of the test results in this study would be considered acceptable.
In summary, based on these studies, the following recommendations are tentatively proposed. 
